The EDEM2 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the EDEM2 gene has been disrupted, enabling loss-of-function studies in a human cervical cancer model. This polyclonal product provides a heterogeneous pool of knockout cells, each harboring a targeted gene disruption that abrogates EDEM2 expression, allowing researchers to investigate the functional consequences of EDEM2 deficiency without clonal selection. The knockout is achieved through general CRISPR/Cas9-mediated gene editing, generating a versatile tool for investigating endoplasmic reticulum-associated degradation (ERAD) and related pathways.
The host HeLa cell line is an immortalized epithelial cell line derived from a cervical adenocarcinoma, positive for human papillomavirus 18 (HPV18). HeLa cells are widely employed in cancer research due to their robust growth, stable karyotype, and well-characterized biology. As an adherent cell type with heterogeneous morphology, they serve as a reliable model for studying fundamental cellular processes, including protein quality control and stress responses. Their viral origin also renders them valuable for host?Cpathogen interaction studies, particularly regarding HPV-associated oncogenesis and viral manipulation of host ER pathways.
EDEM2 (ER degradation-enhancing alpha-mannosidase-like protein 2) is a crucial component of the ERAD pathway, responsible for recognizing mannose-trimmed N-glycans on misfolded glycoproteins within the ER lumen. It interacts with lectins OS-9 and XTP3-B to direct substrates to the SEL1L?CHRD1 retrotranslocation complex, where they are ubiquitinated and extracted into the cytosol through the action of VCP/p97 for proteasomal degradation. EDEM2 acts downstream of the unfolded protein response (UPR) sensors IRE1, ATF6, and XBP1, and its expression is upregulated under ER stress. Key downstream targets include misfolded glycoproteins and specific ERAD substrates such as CD147 and BACE457. By facilitating the clearance of these proteins, EDEM2 maintains ER homeostasis and prevents cytotoxic accumulation of aberrant proteins.
In the HeLa context, EDEM2 knockout impairs the disposal of mannose-trimmed ERAD substrates, leading to their accumulation and the induction of ER stress. This chronic stress activates the UPR, triggering compensatory signaling cascades that can promote cell survival or apoptosis depending on the severity and duration of stress. Given HeLa??s HPV18-positive status, viral proteins may interact with the ERAD machinery, making this model particularly relevant for examining how oncoviruses subvert protein quality control. Consequently, this polyclonal knockout product serves as a powerful system to dissect ERAD-dependent regulation of viral oncogenesis and cancer cell adaptation to proteotoxic stress.
This knockout cell pool is ideal for a broad range of research applications, including mechanistic studies of ERAD substrate recognition and retrotranslocation, UPR signaling dynamics, and the interplay between ER stress and cancer cell survival. It can be employed in host?Cpathogen interaction assays to explore how HPV or other viruses exploit EDEM2-dependent degradation. Representative assays include Western blotting for CD147 accumulation, RT-qPCR for UPR target genes (e.g., BiP, CHOP), cycloheximide chase experiments to measure protein half-life, flow cytometry with ER stress reporters, immunofluorescence to assess ER morphology, and proteasome activity measurements. For further details, please contact Ascent Research to discuss how this product can accelerate your investigations.
